What is the primary objective of mutual recognition agreements in pharmaceutical regulations? Response:

Question

Options

• ATo create a single pharmaceutical market across countries.
• BTo standardize the branding of pharmaceutical products.
• CTo recognize the regulatory inspections and approvals of other jurisdictions.
• DTo unify the prices of pharmaceutical products globally.

• A
  2% (1)
• B
  12% (6)
• C
  80% (39)
• D
  6% (3)

Explanation

Mutual recognition agreements (MRAs) allow countries to accept each other's regulatory inspections and approvals as equivalent, avoiding costly duplication of reviews - meaning if Country A has already approved a drug or inspected a facility, Country B can recognize that work rather than repeating it. Option A is wrong because MRAs don't eliminate separate markets or merge regulatory bodies; each country retains its own system. Option B is incorrect because MRAs have nothing to do with branding or labeling standards. Option D is wrong because pricing is an economic/policy matter entirely outside the scope of regulatory MRAs.

Memory tip: Think of MRAs as a "trusted colleague" arrangement - if a respected colleague already reviewed something, you don't redo their work, you recognize it. The word "recognition" in the answer mirrors the term "mutual recognition" itself, making C the easiest answer to anchor.

No community discussion yet for this question.